USE OF URAPIDIL - ANTIHYPERTENSIVE DRUG WITH DOUBLE ACTION - NEW DIRECTION IN TREATMENT OF HYPERTENSIVE CRISES
https://doi.org/10.20996/1819-6446-2014-10-5-559-564
Abstract
Results of clinical trials devoted to urapidil, antihypertensive drug having central and peripheral mode of actions are reviewed. Target groups of patients for urapidil use are specified. Dosage regimen and methods of urapidil use in different clinical situations with acute increase in arterial blood pressure are described in details.
About the Authors
V. R. AbdrakhmanovRussian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
N. I. Gaponova
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
N. F. Plavunov
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
References
1. Giilis R.A., Kellar K.J., Quest J.A., et al. Experimental studies on the neurocardiovascular effects of urapidil. Drugs 1988; 35: 20-33.
2. Kolassa N., Beller K.D., Sanders K.H. Involvement of brain 5HT1A - receptors in the hypotensive response to urapidil. Am J Cardiol 1989; 64: 7-10.
3. Sanders K.H., Beller K.D., Eltze M., et al. Urapidil and some anaglogs with high affinities for. serotonin1A and α1- adrenoceptor binding sites show potent hypotensive activity upon central administration. Current Оpinion Cardiol 1989; 4: S49- S55.
4. Giuntoli F., Gabbani S., Natali A. et al. Treatment of hypertensive emergencies with urapidil. Cur Ther Res 1991; 49: 296-299.
5. Dooley M., Goa K. L. Urapidil A reappraisal of its use in the management of hypertension. Drugs 1998; 56: 929-55.
6. Van Zwieten P.A, Blauw G.J., van Brummelen P. Pharmacological profile of antihypertensive drugs with serotonin receptor and α-adrenoceptor activity. Drugs 1990; 40:1-8.
7. Mancia G., Fagard R., Narkiewiez K., et al. Diabetes Care 2011; 34: 304-7.
8. Semenova E.V., Golikov A.P., Ryabinin V.A., Luk'yanov M.M. Treatment of hypertensive crises in an integrateddynamic control. TOP Meditsina 1998; (2): 6-8. Russian (Семенова Е.В., Голиков А.П., Рябинин В.А., Лукьянов М.М. Лечение гипертонических кризов с использованием комплексного динамического контроля. ТОП Медицина 1998; (2): 6-8.
9. Alijotas-Reig, Bove-Farre, De Cabo-Frances et al. Effectiveness and Safety of Prehospital Urapidil for Hypertensive Emergencies. Amer J of Emergency Med 2001; 2: 130-3.
10. Vao D.К, Jia S.Q., Wang L. et al. Therapeutic effect of urapidil on myocardial perfusion in patients with ST – elevation acute coronary syndrome. Eur J Int Med 2009; 20: 152-7.
11. Schreiler W., Woisetschlager C., Binder M. et al. Effect of nitroglycerin or urapidil on hemodinamic, metabolic and respiratory parameters in hypertensive patients with pulmonary edema. Intensive Care Med 1998; 24: 557-63.
12. Adnot S., Radermacher P., Andrivet P., et al. Effects of sodium nitroprusside and urapidil on gas exchange and ventilation: perfusion ratios in patients with congestive heart failure. Drugs 1990; 40: 65-6.
13. Cazzola M., Spinazzi A., Santangelo G., et al. Acute effects of urapidil on airway response in hypertensive patients with chronic obstructive pulmonary disease. Drugs 1990; 40: 71-2.
14. Zadionchenko VS, Pogonchenkova IV, Adasheva TV. Arterial hypertension in chronic obstructive pulmonary disease. Moscow: Anaharsis; 2005. Russian (Задионченко В.С., Погонченкова И.В., Адашева Т.В. Артериальная гипертония при хронической обструктивной болезни легких. М.: Анахарсис; 2005).
15. Späh F., Kottmann R., Grosser K.D., et al. Effects of urapidil in patients with mild pulmonary vascular hypertension. Drugs 1990; 40: 69 -70.
16. Castelhy P.A., Lear S., Lear E., et al. Intrapulmonary shunting during induced hypotension. Anesthesia and Analgesia 1982; 61: 231-5.
17. Sivak E.D., Starr N.J., Grave J.W., et al. Extra vascular lung water values in patients undergoing coronary artery bypass surgery. Critic Care Med 1982; 10: 593-6.
18. Mollhoff T., Rosiers P., van Aken H. Urapidil, sodium nitroprusside and nitroglycerin: effects on haemodiynamics, venous admixture and arterial oxygenation after coronary artery bypass grafting. Drugs 1990; 40: 73-6.
19. Wallard R., Karp R.B., Reves J.G., et al. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery. A study of hemodynamic and humoral factors. Am J Cardiol 1980; 46: 559-65.
20. Castelhy P.A. Lcar S., Cottrcll J.E., et al. Intrapulmonary shunting during induced hypotension. Anesthesia and Analgesia 1982; 61: 231-5.
21. Flaherty J.T., Magee P.A., Gardner T.L., et al. Comparison of intravenous nitroglycerin and sodium nitroprusside for treatment of acute hypertenston developing after coronary artery bypass surgery. Circulation 1982; 65: 1072-7.
22. European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
23. Levine OS, Ugoltseva NI, Dudarova MA. Control of blood pressure in acute stroke. Aktual'nye Voprosy Bolezney Serdtsa i Sosudov 2010; 1: 28-34. Russian (Левин О.С., Угольцева Н.И., Дударова М.А. Контроль артериального давления в остром периоде инсульта. Актуальные Вопросы Болезней Сердца и Сосудов 2010; 1: 28-34).
24. Anderson C.S., Heeley E., Huang Y. et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial Lancet Neurol 2008; 7: 391-9.
25. Hirschl M.M., Binder M., Bur A. et al. Safety and efficacy of urapidil and sodium nitroprusside in the treatment of hypertensive emergencies. Intensive Care Med 1997; 23: 885-9.
26. Guidelines for the Early Managementof Patients With Acute Ischemic Stroke : J Amer Heart Association 2013; 1-87.
27. Buch. J. Urapidil, a Dual Acting Antihypertensive Agent: Current Usage Considerations. Adv Ther 2010; 7: 1-18.
Review
For citations:
Abdrakhmanov V.R., Gaponova N.I., Plavunov N.F. USE OF URAPIDIL - ANTIHYPERTENSIVE DRUG WITH DOUBLE ACTION - NEW DIRECTION IN TREATMENT OF HYPERTENSIVE CRISES. Rational Pharmacotherapy in Cardiology. 2014;10(5):559-564. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-5-559-564